EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH

View source ↗

Summary

Vabysmo (faricimab) has been authorised by the EMA for indications including wet age-related macular degeneration, macular edema, and diabetes-related complicat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes-related Eye Complications
• Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications. MAH: Roche Registration GmbH. Decision date: 09/07/2026